Journal article

Economic Evaluation of Single versus Combination Immuno-Oncology Therapies: Application of a Novel Modelling Approach in Metastatic Melanoma.

Eddie J Gibson, Najida Begum, Ian Koblbauer, George Dranitsaris, Danny Liew, Phil McEwan, Yong Yuan, Ariadna Juarez-Garcia, David Tyas, Clive Pritchard

ClinicoEconomics and Outcomes Research | Published : 2020


Background: Existing economic model frameworks may not adequately capture the atypical treatment response patterns in immuno-oncology (I-O) compared with conventional therapies and thus may fail to represent the full clinical value associated with disease dynamics and improved survival. Objective: A cost-effectiveness analysis (CEA) of the I-O Regimen (nivolumab/ipilimumab) versus ipilimumab alone in advanced melanoma was carried out by applying a 5-state partitioned survival model (PSM) as a case study, to explore the I-O treatment response and clinical outcomes. The findings were compared with those of a conventional 3-state PSM. Materials and Methods: The case study extends the convention..

View full abstract